121 related articles for article (PubMed ID: 29806672)
1. [O6-methylguanine-DNA-methyltransferase (MGMT) expression in patients with glioblastoma multiforme].
Jiménez D; Matamala JM; Chiti A; Vergara C; Tissera C; Melo R; Cartier L
Rev Med Chil; 2018 Jan; 146(1):7-14. PubMed ID: 29806672
[TBL] [Abstract][Full Text] [Related]
2. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Watanabe R; Nakasu Y; Tashiro H; Mitsuya K; Ito I; Nakasu S; Nakajima T
Brain Tumor Pathol; 2011 Apr; 28(2):127-35. PubMed ID: 21331613
[TBL] [Abstract][Full Text] [Related]
3. O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.
Chahal M; Abdulkarim B; Xu Y; Guiot MC; Easaw JC; Stifani N; Sabri S
Mol Cancer Ther; 2012 Nov; 11(11):2440-50. PubMed ID: 22986464
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.
Miyazaki M; Nishihara H; Terasaka S; Kobayashi H; Yamaguchi S; Ito T; Kamoshima Y; Fujimoto S; Kaneko S; Katoh M; Ishii N; Mohri H; Tanino M; Kimura T; Tanaka S
Neuropathology; 2014 Jun; 34(3):268-76. PubMed ID: 24397721
[TBL] [Abstract][Full Text] [Related]
5. In situ detection of O6-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors.
Ohe N; Saio M; Kijima M; Tamakawa N; Suwa T; Kojima Y; Yano H; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2003 Mar; 22(3):543-9. PubMed ID: 12579307
[TBL] [Abstract][Full Text] [Related]
6. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
Kamiryo T; Tada K; Shiraishi S; Shinojima N; Kochi M; Ushio Y
Neurosurgery; 2004 Feb; 54(2):349-57; discussion 357. PubMed ID: 14744281
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
8. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
9. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
[TBL] [Abstract][Full Text] [Related]
11. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
12. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
13. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.
Dahlrot RH; Dowsett J; Fosmark S; Malmström A; Henriksson R; Boldt H; de Stricker K; Sørensen MD; Poulsen HS; Lysiak M; Söderkvist P; Rosell J; Hansen S; Kristensen BW
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):172-184. PubMed ID: 28574607
[TBL] [Abstract][Full Text] [Related]
15. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
[TBL] [Abstract][Full Text] [Related]
16. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
18. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Balaña C; Ramirez JL; Taron M; Roussos Y; Ariza A; Ballester R; Sarries C; Mendez P; Sanchez JJ; Rosell R
Clin Cancer Res; 2003 Apr; 9(4):1461-8. PubMed ID: 12684420
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
Nakagawa T; Ido K; Sakuma T; Takeuchi H; Sato K; Kubota T
Neuropathology; 2009 Aug; 29(4):379-88. PubMed ID: 19019175
[TBL] [Abstract][Full Text] [Related]
20. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
